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胞的分离、浸润和远端转移，且具有向脑部转移的倾向。 
我们应用斑点印迹（Dot Blot）方法研究了喉癌组织中的 PSA 的表达，结果
发现喉癌中癌组织 PSA 表达的阳性率为 95.6%（43/45），癌旁组织为 75.5%
（37/49），淋巴结组织为 80.0%（8/10），癌组织与癌旁组织的 PSA 阳性率差
异有显著统计学意义，说明 PSA 在喉癌组织中表达的阳性率很高，且远高于文
献报道的其他肿瘤组织，如小细胞肺癌等；PSA 的表达与性别、年龄、肿瘤分化
程度、发生部位无关；PSA 表达的阳性率与 TNM 分期中的 T 因素有关，说明喉
癌向周围组织浸润的程度越高，PSA 表达的阳性率越高；有淋巴结转移喉癌的癌
组织、癌旁组织和淋巴结 PSA 的阳性率均高于没有淋巴结转移的相应喉癌组织，

















Malignant tumour is a serious disease that threat to human health, and has an 
increasing trend in recent years. Laryngeal carcinoma cell is derived from laryngeal 
mucous membrane epithelium of larynx. The number of laryngeal tumours in all kinds 
of tumours accounts for about 1% to 5%, but less than nasopharyngeal and nasal sinus 
cancer in the ENT tumours. Laryngeal carcinoma easily happens brain metastases. 
Smoking, drinking, long-term inhaled harmful substances and papilloma virus 
infection related to carcinoma of larynx. The 5-year survival rate is more than 70%, 
10-year survival rate is about 50%. In recent years, its incidence is increasing 
gradually. Therefore, studying the pathogenesis of laryngeal cancer and looking for a 
marker to judge the prognosis of patients with laryngeal cancer has been such a hot 
issue in the field.  
The surface of cells is rich in a series of information from sugar molecules. It’s 
decorated with fat and protein, which will carry messages to the special cells, to 
control the physiological processes of cells. Polysialic acid (PSA) belongs to this kind 
sugar complex on the surface of cells. It mainly connects with neural cell adhesion 
molecule (NCAM). And this connection controls the interaction between the adjacent 
cells. 
PSA is sialic acid monomer with the connection of α-2,8 and/or α-2,9 to produce 
uniform linear polymer, mainly attached to NCAM. Polysialylated form of NCAM 
(PSA-NCAM) plays its role. Two kinds of Polysialyltransferases-ST8Sia II (STX) and 
ST8Sia IV (PST) catalyze NCAM polysialylating. Polysialyltransferases belong to six 
gene encoding α-2,8 aminoethanoic acid transferase family. 
PSA-NCAM plays a key role in the process of regulating cell migration, adhesion, 
axon bundle, synapse formation and development of nervous system and reshape. 
Because of its a lot of negative charge, it has hydrophilicity and could form a larger 















membrane or NCAM with other molecules, polysialylated form increasing the 
distance between the adjacent cell membrane, thereby the interactions between the 
cell membrane lost. In human normal embryonic brain development, after translated 
NCAM needs to decorate to play polysialylating. But in normal adults tissues, in 
addition to the hypothalamus, the hippocampus, olfactory bulb and some other 
synapse formation and nerve continuous regeneration, NCAM in other parts of the 
tissues lacks of PSA expression. But studies show that PSA also exists in non-small 
cell lung cancer (NSCLC)[1], small cell lung cancer (SCLC)[2], Wilms’ tumour[3], 
rhabdomyosarcoma[4], neuroblastoma[5], colorectal cancer[6], nerve cell tumour[7], 
namely PSA in these tumour tissues appeared again, and the expression of PSA 
promote cancer cell separation, infiltration and distal metastasis, and enhance the 
tendency to brain metastases. 
We applied the method of Dot Blot to study the PSA expression in the laryngeal 
carcinoma. The results is found that the expression rate of PSA in tumour tissues of 
the laryngeal carcinoma is 95.6% (43/45), in adjacent tissues is 75.5% (37/49), in 
lymph nodes is 80.0% (8/10). There is a prominent statistically meaning on the PSA 
expression difference between cancer tissues and adjacent tissues. They could tell us 
that there is a significant high expression rate of PSA in tumour tissues of the 
laryngeal carcinoma, far higher than other tumour tissues reported in the literature, 
such as small cell lung cancer, etc. The expression of PSA has nothing to do with 
gender, age, tumour differentiation, location. The positive rate of PSA expression has 
relation with T factors of the TNM staging, which suggest us that the more highly 
laryngeal cancer infiltrate into the surrounding tissues, the higher positive PSA 
expression. Tumour tissues, adjacent tissues and lymph nodes of the patients with 
lymph node metastasis have a higher expression rate of PSA than without lymph node 
metastases, which indicate that the PSA expression promotes lymph node metastases 
in the laryngeal carcinoma. 
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PSA Polysialic acid 多聚唾液酸 
NCAM Neural cell adhesion molecule 神经细胞粘附分子 
PSA-NCAM 
Polysialylated form of the neural cell adhesion molecule 
 多聚唾液酸化神经细胞粘附分子 
SCLC Small cell lung cancer 小细胞肺癌 
NSCLC Non-small lung cancer 非小细胞肺癌 
STX ST8Sia II，ST8 α-N-acetylneuraminide α-2，8-sialyltransferase II
多聚唾液酸转移酶 II 
PST ST8Sia IV，ST8 α-N-acetylneuraminide α-2，8-sialyltransferase 
IV 多聚唾液酸转移酶 IV 
NC Nitrocellulose membrane 硝酸纤维素膜 
IHC Immunohistochemistry 免疫组织化学法 
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1 
第 1 章 绪 论 
据 2009 年世界卫生组织（WHO）统计，世界癌症新发病例每年增长 1000
万，因癌症死亡人数达到 700 万。中国癌症的发病率不断增加，每年新发病例约
230 万人，每年因癌症死亡的人数占 160-170 万人，据预测，到 2020 年，中国将
有 550 万新发癌症病例，而死亡人数将达到 400 万！ 
喉癌（Carcinoma of larynx）是头颈部 常见的恶性肿瘤之一，来源于喉粘
膜上皮组织，淋巴结转移是喉的主要生物学特征，是肿瘤患者致死的主要原因[8]。














1.1 PSA 简述 
1.1.1 PSA 的发现和理化特点 
1957 年，Barry 和 Goebel 等[14]首先在大肠杆菌 Escherichia coli K2235 和 K21
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菌 Salmonella toucra 048，弗氏柠檬酸杆菌 Citrobacter freundii 05 中也发现
PSA[15]。20 世纪 80 年代，研究发现 PSA 为一种线性、均一多聚的 α-2，8 唾液
酸，其特异性附着在 NCAM 上，在自然界中广泛分布，如噬菌性病原体，包括
神经侵染性的 Escherichia coli K1 和 Neisseria meningitidis Gp B，以荚膜多糖的
形式表达，之后研究相继发现其也在鱼卵、海胆卵、动物大脑、人类大脑和部分
肿瘤中表达， PSA 主要载体为 NCAM，多聚唾液酸化 NCAM（Polysialylated form 
of the neural cell adhesion molecule，PSA-NCAM）在胚胎大脑中非常丰富，而在
成熟大脑中的大部分 NCAM 为非聚唾液酸化。 
PSA 是一种白色不定型高聚合物，水溶性好，粘度低，生物相容性好，具有
生物可降解性[15]，在酸的作用下容易降解成唾液酸单体。 
1.1.2 PSA 的结构和功能 
唾液酸是以九碳糖神经氨酸（5-amino-3，5-dideoxy-D-glycero-D-galactononuls 
-onic acid）为基本结构的一族衍生物的总称，共 50 多种[16]，其中 N-乙酰神经氨
酸（N-acetylneuraminic acids，Neu5Ac，如图 1A）、N-羟乙酰神经氨酸（N-glycolyl 
neµraminic acid，Neu5Gc，如图 1B）和 2-酮基-3-脱氧九酮糖酸（2-keto-3-deoxy- 




单体，不能产生 Neu5Gc 和 KDN，而人体内出现的 Neu5Gc 和 KDN 主要来源于
食物或病变，如肿瘤。Neu5Ac 分子的 N-乙酰基被羟基化则生成 Neu5Gc，Neu5Gc
出现在鲑鳟鱼卵、食物（主要为红色肉类牛羊肉等和奶制品）[19]以及猿的高等动
物体内，但人体内存在抗 Neu5Gc 抗体[20]；Neu5Ac 分子上 C5 的氨基被羟基取代
后便转化为 KDN，KDN 为新发现的唾液酸家族成员，1988 年在鱼卵中被首次发
现[21]，后有报道 KDN 存在于鱼卵和鱼卵巢液中、人类胚胎红血球和卵巢癌中，
其有可能是早期癌症的诊断指标[22]，但相关文献甚少。 
近的研究表明，PSA 由两个或两个以上的 Neu5Ac 或 Neu5Gc 或短链的
KDN 通过 α-2，8 键或者 α-2，9 键或者两者交替连接形成，哺乳动物中主要为 α-2，
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图 1-1 唾液酸家族的 3 个核心单体 
Fig.1-1 Three main members of the sialic acid (Sia) family 
注： A：N-acetylneuraminicacid(Neu5Ac)；B：N-glycolylneuraminicacid(Neu5Gc)；C：Ketodeoxynonulosonicacid 
(KDN) 
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